// App-Quantinova.ai

: Real-world use of darolutamide, enzalutamide, and apalutamide for non-metastatic castration-resistant prostate cancer (DEAR).

Researchers

Presenter

  • Daniel J. George

Principal Investigators

  • Nasreen Khan

  • Niculae Constantinovici

  • Javeed Khan

  • Guifang Chen

  • Julie Xu

  • Jorge A. Ortiz

  • Alicia K. Morgans

Medical Centers

  • Bayer Canada, Mississauga, ON, Canada

  • Bayer Consumer Care AG, Basel, Switzerland

  • Bayer, Reading, United Kingdom.

  • Bayer HealthCare, Whippany, NJ

  • Dana-Farber Cancer Institute, Boston, MA

  • Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC

Locations

  • United Kingdom

  • Switzerland

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • Enzalutamide

Outcome

  • N/A

Study Design

  • Observational

Phase

  • NA

Study Id's

  • NCT05362149

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved